Wedmont Private Capital Has $262,000 Position in Sanofi $SNY

Wedmont Private Capital lessened its position in Sanofi (NASDAQ:SNY) by 6.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,367 shares of the company’s stock after selling 383 shares during the period. Wedmont Private Capital’s holdings in Sanofi were worth $262,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nuveen LLC acquired a new stake in shares of Sanofi in the first quarter valued at about $177,831,000. Federated Hermes Inc. increased its stake in shares of Sanofi by 58.5% in the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after buying an additional 1,456,269 shares during the period. OLD Mission Capital LLC acquired a new stake in shares of Sanofi in the first quarter valued at about $48,938,000. Raymond James Financial Inc. increased its stake in shares of Sanofi by 15.1% in the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after buying an additional 425,597 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Sanofi by 8,703.0% in the first quarter. GAMMA Investing LLC now owns 335,921 shares of the company’s stock valued at $18,630,000 after buying an additional 332,105 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Down 0.1%

Shares of NASDAQ:SNY opened at $47.64 on Monday. Sanofi has a 52-week low of $44.73 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The business’s 50 day simple moving average is $48.49 and its two-hundred day simple moving average is $50.75. The firm has a market cap of $116.98 billion, a P/E ratio of 11.45, a PEG ratio of 1.12 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the business earned $1.73 EPS. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. As a group, research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on SNY. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Guggenheim restated a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.